ISG15 is strongly induced after type I IFN stimulation producing a protein comprised of two ubiquitin-like domains. Intracellularly, ISG15 can be covalently linked and modify the function of target proteins (ISGylation). In addition, free unconjugated ISG15 can be released from cells. We found that ISG15 is released in the serum of Toxoplasma gondii infected mice early after infection in a type-I IFN independent manner. Once in the extracellular space, free ISG15 forms dimers and enhances the release of key cytokines involved in the immune response to the parasite: IL-12, IFN-γ, and IL-1β. Its action is dependent on an actively invading and replicating live parasite. ISG15 induces an increase of IL-1β later during infection by leading to increased IL-1β producing CD8α+ dendritic cells at the site of infection. Here, we define for the first time the molecular determinants of active free ISG15 and link ISG15 to IL-1β production by CD8α+ dendritic cells. Thus we define ISG15 as a novel secreted modulator of the cytokine response during Toxoplasma infection.
ISG15 is a 15 kDa member of the family of interferon stimulated genes (ISGs) that contains two ubiquitin-like domains connected by a proline peptide linker.
Similar to ubiquitin, ISG15 can be conjugated to intracellular host and viral proteinsemploying a cascade of E1 (UBE1L), E2 (UbcH8), and E3 conjugating enzymes. This ISGylation can modify protein function (LIT) and extensive studies have elucidated the role conjugated ISG15, mostly in the context of viral infection [1] [2] [3] . Recently the function of intracellular conjugated ISG15 has been extended to bacterial infections when it was found that Listeria infection induces ISGylation in non-phagocytic cells 4 . Interestingly, this ISG15 induction was type I IFN independent and lead to the release of IL-8 and IL-6 restricting bacterial replication 4 . Free ISG15 can also be released from the cell to the extracellular space and is detectable in the serum 5 This extracellular free ISG15 it has long been appreciated to play an important role. In vitro studies suggested a role for free ISG15 as a cytokines able to induce IFN-γ secretion from NK cells 3 and CD3 + lymphocytes in vitro 6, 7 . Additionally, ISG15 was isolated from red blood cells of mice infected
with Plasmodium yoelii and shown to act as a chemotractant for neutrophils 8 .
However the in vivo function of free ISG15 remains ill-defined, and only two studies addressed the role offree ISG15 in an in vivo setting 9, 10 . In a neonatal model of infection with Chikungunya virus, free ISG15 functions as an immunomodulator of proinflammatory cytokines, providing the first evidence that free ISG15 contributes to the host response during infection in the whole organism 9 . Most strikingly, it was recently demonstrated that ISG15 is a potent IFN-γ-inducing "cytokine" playing an essential role in anti-mycobacterial immunity 10 . Free extracellular ISG15 is effective alone or in synergy with to induce IFN-γ secretion from granulocytes and NK cells in response to mycobacterial infection 10 . The ISG15-IFN-γ circuit may therefore be an "innate" complement to the more "adaptive" IL-12-IFN-γ circuit 10 .
Toxoplasma gondii is an obligate intracellular parasite that can infect virtually any nucleated cell. The active acute infection is believed to be mostly controlled by IFNγ, however, the parasite is never eliminated from an infected host and establishes a chronic infection at immune privileged sites, such as the brain and the heart 11 . In immunocompromised adults, this intracellular parasite dormant state in the brain reactivates and leads to the development of toxoplasmosis. The subsequent uncontrolled parasite replication causes life-threatening brain damage that is characterized by brain abscesses and necrotic areas. Two defence molecules, IL-12 and IFN-γ, orchestrate protective immunity in infected hosts 11 . The role of the IL-12-IFN-γ circuit during Toxoplasma gondii infection has been extensively characterised 11, 12 .
Toxoplasma gondii infection triggers the release of a broad spectrum of molecules that can control the immune response to the parasite (LIT). In particular recent work has drawn much attention to the role of the inflammasome and IL-1β in the control of Toxoplasma infection [1] [2] [3] [13] [14] [15] . Host protective immunity against Toxoplasma is highly dependent on the inflammasome sensors NLRP1 and NLRP3 4, 15 . Moreover, the activation of the inflammasome is also dependent on the Toxoplasma strain dependent, with type II parasite being able to induce NLRPs activation and IL-1β release 4, 14, 15 .
Given the strong dependence of a Toxoplasma infection on IL- 
Results

Toxoplasma gondii infection induces to the type I IFN-independent
production and release of free ISG15 into the serum
To analyse if ISG15 is released during Toxoplasma gondii infection, we infected mice with Toxoplasma type II and monitored ISG15 levels in the serum during the acute phase of infection. We first determined the serum ISG15 levels by ELISA ( Fig 1A) . As early as day 2 post-infection (p.i.) the amount of ISG15 released was higher than in uninfected control mice ( Fig.   1A ) and its levels continue to rise until day 4 p.i. (Fig. 1A) . To ascertain specificity of the commercial ELISA, we demonstrated that no signal is observed in the serum of Toxoplasma-infected ISG15 -/-mice (Fig. S1A ).
Likewise, recombinant ISG15 protein was detected in a dose-dependent manner (Fig. S1B ). ISG15 may exist in the extracellular spaces as a monomeric or dimeric protein 16 . To analyse the quaternary structure of free ISG15 during Toxoplasma infection, we analysed the serum of infected mice by SDS-PAGE and immunoblotting under non-reducing conditions. We confirmed the release of ISG15 early upon infection and noticed the presence of a 30 kDa band that may represents dimeric ISG15 (Fig. 1B top) . The protein band intensity from four experiments was quantified by ImageJ software and the immunoblot for the IgG heavy chain was used to normalize the levels of ISG15 in the serum (Fig. 1B bottom) . 1D ). We concluded that early after infection Toxoplasma induces the release of ISG15 in a type-I IFN independent way. To further corroborate this finding we also analysed the expression of a panel of classical IFN target genes in the spleen of infected mice at day 4 p.i. (Fig. S1C) . None of these genes were increased in expression upon Toxoplasma infection. To dissect the role of free ISG15 during Toxoplasma infection, we infected mice with Toxoplasma type II and treated them with 1 µg of recombinant murine ISG15 at day 0, 1 and 2 p.i. by intra-peritoneal injection. As controls we employed both untreated Toxoplasma infected mice and naïve mice (Fig.   S2A ). We determined the levels of key cytokines released early after infection.
Interestingly, shortly upon infection, ISG15-treated mice showed a modest but significant increase in IFN-γ, IL-12 and IL-1β, at different time points compared to infected but untreated mice ( Fig. 2A) . In particular, IL-1β secretion was consistently increased at all time points in ISG15-treated infected mice. Importantly, no increase in these cytokine levels were seen upon ISG15 treatment of uninfected mice, demonstrating that ISG15 alone is not sufficient to increase cytokine secretion, but only does so in the context of an infection (Fig. S2A) . Additionally, this result ensures that the preparation of recombinant ISG15 is endotoxin free. To unequivocally assess if the cytokine modulatory function of ISG15 requires a process of active invasion from the parasite, we infected mice with live-, γ-irradiated-, or heat killed Toxoplasma. In each case we either only infected the mice or in addition treated the animals with recombinant ISG15.
Recombinant ISG15 injection only increased cytokine release when mice were infected with live, actively replicating parasites (Fig. 3A) , suggesting that ISG15-dependent modulation of cytokine levels during the early phase of infection is strictly dependent on active invasion and replication of the parasite.
Free ISG15 needs to dimerise to enhances the release of IL-12, IFN-γ and IL-1β during Toxoplasma infection
As we had noted the appearance of an anti-ISG15 immunoreactive 30 kDa band that may represent dimeric ISG15, we speculated that a dimeric form of ISG15 there is causative for the cytokine induction (Fig. 1B) . As previously described, the disulphide bonds between cysteines in the hinge region might be responsible for ISG15 dimer formation 26 . 
Discussion
We demonstrate that free extracellular ISG15 is involved in the regulation of the immune response to a protozoan infection with Toxoplasma gondii in vivo.
We show that this free form of ISG15 is released in the serum early upon For in vivo experiments infected mice were treated with ISG15 (1µg/mouse) or treated with either PBS, buffer from the gel filtration or nothing with no difference observed.
Reagents and Antibodies
Anti-ISG15 rabbit sera, gently gift of Peter Knobeloch, was used as primary ELISA Pierce TMB substrate kit (34021) was from Thermo Fisher Scientific.
Dulbecco's PBS was from VWR (21-031-CV)
Immunoblot and Comassie Blue staining
Immunoblot was used to quantitatively detect specific protein bands after separation of proteins on pre-casted 4-20% gradient SDS-PAGE gel 
Statistical analysis
All statistical significance analyses were performed using Prism software C57BL6 mice were infected with 25,000 type II tachyzoites i.p. and serum samples were collected at different time points p.i.. A) Serum ISG15 levels during Toxoplasma infection measured by ELISA. 6 mice/group. One of three independent experiments. B) ISG15 immunoblot on serum samples. On the top, one representative blot of ISG15 and total IgG heavy chain used as loading control. On the bottom is plotted the quantification of four independent experiments. C) C57BL6 mice were infected with live or heat killed or γ-irradiated tachyzoites i.p., and serum ISG15 levels was assessed at day 4 p.i.. 3 mice/group, one of two independent experiments. D) qPCR for ISG15 and IFNα genes on RNA extracted from peritoneal exudate cells from uninfected and at day 2, 4, 7 and 9 p.i., 6 mice per group. One of two independent experiments. Statistics for all were analysed by two way ANOVA statistic with Tukey's multiple comparisons test, *p<0.05; ***p<0.0005; ****p<0.00005. CD8a DCs Figure S4 : C57BL6 mice were either infected with 25,000 type II tachyzoite i.p. and treated with recombinant ISG15 or infected only. Mice were sacrified 4 days post infection and cells were purified from peritoneal exudate. A) Gating strategy (top) and quantification (bottom) for the staining used to analyse the innate cell populations, 3 mice per group. One of three independent experiments. B) Gating strategy for the staining used to analyse CD8α+ and CD103 DCs, 3 mice per group. One of three independent experiments. Statistics were analysed by two way ANOVA statistic with Tukey's multiple comparisons test, ***p<0.0005.
